ID2 and lymphoma: Collectively, these data point to a regulatory circuitry that underpins the mechanism by which Id2 and Id3 act to antagonize an innate variant TFH-specific program of gene expression, maintain thymocyte quiescence, and suppress the development of lymphoma.